Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.

Vuong TN, Ho MT, Ha TD, Phung HT, Huynh GB, Humaidan P

Fertility and sterility31 Oct 2015Cited by 43 (Europe PMC)

PMID26523330DOI10.1016/j.fertnstert.2015.10.014PepBankPUB-26523330

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In oocyte donors, metaphase II oocyte counts did not differ significantly between triptorelin dose groups.
In plain wordsIn oocyte donors, mature oocyte counts did not differ significantly between triptorelin dose groups.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMetaphase II oocytes
Study
n = 165
Comparator
Triptorelin 0.2, 0.3 and 0.4 mg groups
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2, 0.3 or 0.4 mgAs given in this study (human).
Measurements
Metaphase II oocytes
16 oocytes
0.2 mg
Metaphase II oocytes
15.9 oocytes
0.3 mg
Metaphase II oocytes
14.7 oocytes
0.4 mg
Source sentences
Summary
There were no significant differences between the triptorelin 0.2, 0.3, and 0.4 mg trigger groups with respect to number of metaphase II oocytes (16.0 ± 8.5, 15.9 ± 7.8, and 14.7 ± 8.4, respectively), embryos (13.2 ± 7.8, 11.7 ± 6.9, 11.8 ± 7.0), and number of top-quality embryos (3.8 ± 2.9, 3.6 ± 3.0, 4.1 ± 3.0).
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333001
02HumanRandomized controlled trialEfficacy outcome
In oocyte donors, embryo counts did not differ significantly between triptorelin dose groups.
In plain wordsIn oocyte donors, embryo counts did not differ significantly between triptorelin dose groups.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeEmbryo count
Study
n = 165
Comparator
Triptorelin 0.2, 0.3 and 0.4 mg groups
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2, 0.3 or 0.4 mgAs given in this study (human).
Measurements
Embryos
13.2 embryos
0.2 mg
Embryos
11.7 embryos
0.3 mg
Embryos
11.8 embryos
0.4 mg
Source sentences
Summary
There were no significant differences between the triptorelin 0.2, 0.3, and 0.4 mg trigger groups with respect to number of metaphase II oocytes (16.0 ± 8.5, 15.9 ± 7.8, and 14.7 ± 8.4, respectively), embryos (13.2 ± 7.8, 11.7 ± 6.9, 11.8 ± 7.0), and number of top-quality embryos (3.8 ± 2.9, 3.6 ± 3.0, 4.1 ± 3.0).
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333002
03HumanRandomized controlled trialEfficacy outcome
In oocyte donors, top-quality embryo counts did not differ significantly between triptorelin dose groups.
In plain wordsIn oocyte donors, top-quality embryo counts did not differ significantly between triptorelin dose groups.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTop-quality embryo count
Study
n = 165
Comparator
Triptorelin 0.2, 0.3 and 0.4 mg groups
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2, 0.3 or 0.4 mgAs given in this study (human).
Measurements
Top-quality embryos
3.8 embryos
0.2 mg
Top-quality embryos
3.6 embryos
0.3 mg
Top-quality embryos
4.1 embryos
0.4 mg
Source sentences
Summary
There were no significant differences between the triptorelin 0.2, 0.3, and 0.4 mg trigger groups with respect to number of metaphase II oocytes (16.0 ± 8.5, 15.9 ± 7.8, and 14.7 ± 8.4, respectively), embryos (13.2 ± 7.8, 11.7 ± 6.9, 11.8 ± 7.0), and number of top-quality embryos (3.8 ± 2.9, 3.6 ± 3.0, 4.1 ± 3.0).
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333003
04HumanRandomized controlled trialEfficacy outcome
In oocyte donors, progesterone after retrieval was higher with triptorelin 0.4 mg than 0.2 mg.
In plain wordsIn oocyte donors, progesterone after retrieval was higher with triptorelin 0.4 mg than 0.2 mg.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseProgesterone after oocyte retrieval
Study
n: not reported in source
Comparator
Triptorelin 0.2 mg
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.4 mgAs given in this study (human).
Measurements
Progesterone
2.2 ng/ml
0.4 mg, pick-up +6 days
Progesterone
1.1 ng/ml
0.2 mg, pick-up +6 days
Source sentences
Summary
Progesterone level at oocyte pick-up +6 days was significantly higher in the 0.4-mg group (2.2 ± 3.7 ng/ml) versus 0.2 mg (1.1 ± 1.0 ng/ml) and 0.3 mg (1.2 ± 1.6 ng/ml).
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333008
05HumanRandomized controlled trialEfficacy outcome
In oocyte donors, progesterone after retrieval was higher with triptorelin 0.4 mg than 0.3 mg.
In plain wordsIn oocyte donors, progesterone after retrieval was higher with triptorelin 0.4 mg than 0.3 mg.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseProgesterone after oocyte retrieval
Study
n: not reported in source
Comparator
Triptorelin 0.3 mg
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.4 mgAs given in this study (human).
Measurements
Progesterone
2.2 ng/ml
0.4 mg, pick-up +6 days
Progesterone
1.2 ng/ml
0.3 mg, pick-up +6 days
Source sentences
Summary
Progesterone level at oocyte pick-up +6 days was significantly higher in the 0.4-mg group (2.2 ± 3.7 ng/ml) versus 0.2 mg (1.1 ± 1.0 ng/ml) and 0.3 mg (1.2 ± 1.6 ng/ml).
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333009
06HumanRandomized controlled trialSafety outcome
In oocyte donors receiving triptorelin, one patient developed early-onset severe ovarian hyperstimulation syndrome.
In plain wordsIn oocyte donors receiving triptorelin, one patient developed early-onset severe ovarian hyperstimulation syndrome.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableEarly-onset severe OHSS
Study
n = 165
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Severe OHSS
1 patient
Dose group not reported
Source sentences
Summary
One patient developed early-onset severe ovarian hyperstimulation syndrome (OHSS).
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333010
07HumanRandomized controlled trialEfficacy outcome
In oocyte donors, triptorelin 0.4 mg produced higher LH at 24 hours than 0.2 mg.
In plain wordsIn oocyte donors, triptorelin 0.4 mg produced higher LH at 24 hours than 0.2 mg.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLH at 24 hours
Study
n: not reported in source
Comparator
Triptorelin 0.2 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.4 mgAs given in this study (human).
Measurements
LH
9.8 IU/L
0.4 mg at 24 hours
LH
7.3 IU/L
0.2 mg at 24 hours
Source sentences
Summary
Luteinizing hormone levels at 24 hours and 36 hours after trigger was significantly higher with triptorelin 0.4 mg versus 0.2 mg and 0.3 mg (9.8 ± 7.1 IU/L vs. 7.3 ± 4.1 IU/L and 7.2 ± 3.7 IU/L, respectively; 4.6 ± 3.2 IU/L vs. 3.2 ± 2.3 IU/L and 3.3 ± 2.1 IU/L, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333004
08HumanRandomized controlled trialEfficacy outcome
In oocyte donors, triptorelin 0.4 mg produced higher LH at 24 hours than 0.3 mg.
In plain wordsIn oocyte donors, triptorelin 0.4 mg produced higher LH at 24 hours than 0.3 mg.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLH at 24 hours
Study
n: not reported in source
Comparator
Triptorelin 0.3 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.4 mgAs given in this study (human).
Measurements
LH
9.8 IU/L
0.4 mg at 24 hours
LH
7.2 IU/L
0.3 mg at 24 hours
Source sentences
Summary
Luteinizing hormone levels at 24 hours and 36 hours after trigger was significantly higher with triptorelin 0.4 mg versus 0.2 mg and 0.3 mg (9.8 ± 7.1 IU/L vs. 7.3 ± 4.1 IU/L and 7.2 ± 3.7 IU/L, respectively; 4.6 ± 3.2 IU/L vs. 3.2 ± 2.3 IU/L and 3.3 ± 2.1 IU/L, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333005
09HumanRandomized controlled trialEfficacy outcome
In oocyte donors, triptorelin 0.4 mg produced higher LH at 36 hours than 0.2 mg.
In plain wordsIn oocyte donors, triptorelin 0.4 mg produced higher LH at 36 hours than 0.2 mg.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLH at 36 hours
Study
n: not reported in source
Comparator
Triptorelin 0.2 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.4 mgAs given in this study (human).
Measurements
LH
4.6 IU/L
0.4 mg at 36 hours
LH
3.2 IU/L
0.2 mg at 36 hours
Source sentences
Summary
Luteinizing hormone levels at 24 hours and 36 hours after trigger was significantly higher with triptorelin 0.4 mg versus 0.2 mg and 0.3 mg (9.8 ± 7.1 IU/L vs. 7.3 ± 4.1 IU/L and 7.2 ± 3.7 IU/L, respectively; 4.6 ± 3.2 IU/L vs. 3.2 ± 2.3 IU/L and 3.3 ± 2.1 IU/L, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333006
10HumanRandomized controlled trialEfficacy outcome
In oocyte donors, triptorelin 0.4 mg produced higher LH at 36 hours than 0.3 mg.
In plain wordsIn oocyte donors, triptorelin 0.4 mg produced higher LH at 36 hours than 0.3 mg.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLH at 36 hours
Study
n: not reported in source
Comparator
Triptorelin 0.3 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.4 mgAs given in this study (human).
Measurements
LH
4.6 IU/L
0.4 mg at 36 hours
LH
3.3 IU/L
0.3 mg at 36 hours
Source sentences
Summary
Luteinizing hormone levels at 24 hours and 36 hours after trigger was significantly higher with triptorelin 0.4 mg versus 0.2 mg and 0.3 mg (9.8 ± 7.1 IU/L vs. 7.3 ± 4.1 IU/L and 7.2 ± 3.7 IU/L, respectively; 4.6 ± 3.2 IU/L vs. 3.2 ± 2.3 IU/L and 3.3 ± 2.1 IU/L, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Single-center, randomized, parallel, investigator-blinded trial.
Summary · context
One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).
Summary · context
Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.
Report a problemFND-2652333007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02208986

GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study

Vietnam National Universityn = 165Aug 2014 to Mar 2015

Normal Oocyte Donors

Trial page ClinicalTrials.govUpdated 6 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.

Summary

Results from this study10

Registered trials1

GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study

Version history

Subjects

Publication types

MeSH terms

Keywords